VIDEM is developing a small, handheld and low-cost molecular diagnostic device based on innovative
nucleic acid amplification and super sensitive, multiparametric readout. The technology has been developed through state of the art chemistry, bio and nanotechnology. It’s universally applicable for all pathogens, enables multiplex testing and provides accurate test results in less than one hour, instead of days.
CEO: Maria Barklund
GUV Concact: Helena Lundquist